肝门部胆管癌。
Hilar cholangiocarcinoma.
机构信息
José M Ramia, Department of Surgery, Hospital Universitario de Guadalajara, 19002 Guadalajara, Spain.
出版信息
World J Gastrointest Oncol. 2013 Jul 15;5(7):113-4. doi: 10.4251/wjgo.v5.i7.113.
Abstract
Hilar cholangiocarcinoma (HC) is a rare tumor. It accounts for 2/3 of the tumors of the biliary tract. Untreated, prognosis is very poor. Surgery is the only therapy that offers the possibility of cure but is technically very complex. With recent improvements in the therapeutic strategies applied by multidisciplinary teams, survival rates in the different series currently range from 25% to 45%. A group of experts devoted to HC (pathologists, gastroenterologists, radiologists, surgeons and oncologists) have reviewed and updated every open question in HC in a special issue.
摘要
肝门部胆管癌（HC）是一种罕见的肿瘤。它占胆道肿瘤的 2/3。未经治疗，预后非常差。手术是唯一提供治愈可能的治疗方法，但技术上非常复杂。随着多学科团队应用的治疗策略的最新进展，不同系列的生存率目前在 25%至 45%之间。一组专门研究 HC 的专家（病理学家、胃肠病学家、放射科医生、外科医生和肿瘤学家）在一个特刊中回顾和更新了 HC 中的每一个开放性问题。
相似文献
1
Hilar cholangiocarcinoma.肝门部胆管癌。
World J Gastrointest Oncol. 2013 Jul 15;5(7):113-4. doi: 10.4251/wjgo.v5.i7.113.
2
Diagnostic and surgical features of Klatskin tumors.肝门部胆管癌的诊断与手术特征。
Chir Ital. 1999 Jan-Feb;51(1):1-7.
3
Long-term outcome and prognostic factors of intrahepatic cholangiocarcinoma involving the hepatic hilus versus hilar cholangiocarcinoma after curative-intent resection: Should they be recognized as perihilar cholangiocarcinoma or differentiated?肝门部胆管癌累及肝门部与肝门部胆管癌根治性切除术后的长期预后和预后因素：是否应将其视为肝门周围胆管癌或加以区分？
Eur J Surg Oncol. 2019 Nov;45(11):2173-2179. doi: 10.1016/j.ejso.2019.06.014. Epub 2019 Jun 11.
4
Hilar cholangiocarcinoma: preoperative liver optimization with multidisciplinary approach. Toward a better outcome.肝门部胆管癌：多学科方法的术前肝脏优化。实现更好的结果。
World J Surg. 2013 Jun;37(6):1388-96. doi: 10.1007/s00268-013-1980-2.
5
Perioperative Management of Hilar Cholangiocarcinoma.肝门部胆管癌的围手术期管理
J Gastrointest Surg. 2015 Oct;19(10):1889-99. doi: 10.1007/s11605-015-2854-8. Epub 2015 May 29.
6
Benign Tumours and Pseudotumours Within the Porta Hepatis Masquerading as Perihilar Cholangiocarcinoma.肝门部伪装成肝门周围胆管癌的良性肿瘤和假瘤
Klin Onkol. 2019 Fall;32(6):411-425. doi: 10.14735/amko2019411.
7
Current therapy of hilar cholangiocarcinoma.肝门部胆管癌的当前治疗方法。
Hepatobiliary Pancreat Dis Int. 2012 Feb;11(1):12-7. doi: 10.1016/s1499-3872(11)60119-7.
8
Pathological aspects of so called "hilar cholangiocarcinoma".所谓“肝门部胆管癌”的病理学方面。
World J Gastrointest Oncol. 2013 Jul 15;5(7):159-70. doi: 10.4251/wjgo.v5.i7.159.
9
[Klatskin tumor. A study of 15 resected cases].[肝门部胆管癌。15例手术切除病例的研究]
Chirurgie. 1999 Apr;124(2):132-9; discussion 139-40. doi: 10.1016/s0001-4001(99)80055-5.
10
The expression of matrix metalloproteinases in intrahepatic cholangiocarcinoma, hilar (Klatskin tumor), middle and distal extrahepatic cholangiocarcinoma, gallbladder cancer, and ampullary carcinoma: role of matrix metalloproteinases in tumor progression and prognosis.基质金属蛋白酶在肝内胆管癌、肝门部（克氏壶腹肿瘤）、肝外胆管中下段癌、胆囊癌和壶腹癌中的表达：基质金属蛋白酶在肿瘤进展和预后中的作用
Turk J Gastroenterol. 2009 Mar;20(1):41-7.
引用本文的文献
1
Cholangiocarcinoma: a review of the literature and future directions in therapy.胆管癌：文献综述与治疗的未来方向
Hepatobiliary Surg Nutr. 2022 Aug;11(4):555-566. doi: 10.21037/hbsn-20-396.
2
A case series of hilar cholangiocarcinoma: A single surgeon experience over 20-years.肝门部胆管癌病例系列：一位外科医生20年的经验
Ann Med Surg (Lond). 2021 Jan 22;62:239-243. doi: 10.1016/j.amsu.2021.01.059. eCollection 2021 Feb.
3
Preoperative prediction of curative surgery of perihilar cholangiocarcinoma by combination of endoscopic ultrasound and computed tomography.内镜超声与计算机断层扫描联合用于肝门部胆管癌根治性手术的术前预测
United European Gastroenterol J. 2018 Mar;6(2):263-271. doi: 10.1177/2050640617713651. Epub 2017 May 25.
4
Retinoid X receptor α enhances human cholangiocarcinoma growth through simultaneous activation of Wnt/β-catenin and nuclear factor-κB pathways.维甲酸X受体α通过同时激活Wnt/β-连环蛋白和核因子κB信号通路促进人胆管癌生长。
Cancer Sci. 2015 Nov;106(11):1515-23. doi: 10.1111/cas.12802. Epub 2015 Oct 7.
5
The prognostic potential and oncogenic effects of PRR11 expression in hilar cholangiocarcinoma.PRR11表达在肝门部胆管癌中的预后潜力及致癌作用
Oncotarget. 2015 Aug 21;6(24):20419-33. doi: 10.18632/oncotarget.3983.
6
Use of an autologous liver round ligament flap zeros postoperative bile leak after curative resection of hilar cholangiocarcinoma.使用自体肝圆韧带瓣可消除肝门部胆管癌根治性切除术后的胆漏。
PLoS One. 2015 May 4;10(5):e0125977. doi: 10.1371/journal.pone.0125977. eCollection 2015.
7
Imaging and interventions in hilar cholangiocarcinoma: A review.肝门部胆管癌的影像学检查与介入治疗：综述
World J Radiol. 2015 Feb 28;7(2):28-44. doi: 10.4329/wjr.v7.i2.28.
8
Placement of ¹²⁵I seed strands and stents for a type IV Klatskin tumor.¹²⁵I 粒子条及支架置入治疗IV型肝门部胆管癌
World J Gastroenterol. 2015 Jan 7;21(1):373-6. doi: 10.3748/wjg.v21.i1.373.
9
Overexpression of Sig1R is closely associated with tumor progression and poor outcome in patients with hilar cholangiocarcinoma.Sig1R的过表达与肝门部胆管癌患者的肿瘤进展及不良预后密切相关。
Med Oncol. 2014 Dec;31(12):261. doi: 10.1007/s12032-014-0261-8. Epub 2014 Oct 26.
10
Multimodal treatment strategies for advanced hilar cholangiocarcinoma.晚期肝门部胆管癌的多模态治疗策略
Langenbecks Arch Surg. 2014 Aug;399(6):679-92. doi: 10.1007/s00423-014-1219-1. Epub 2014 Jun 25.
本文引用的文献
1
Chemotherapy for cholangiocarcinoma: An update.胆管癌的化疗：最新进展。
World J Gastrointest Oncol. 2013 Jul 15;5(7):171-6. doi: 10.4251/wjgo.v5.i7.171.
2
Pathological aspects of so called "hilar cholangiocarcinoma".所谓“肝门部胆管癌”的病理学方面。
World J Gastrointest Oncol. 2013 Jul 15;5(7):159-70. doi: 10.4251/wjgo.v5.i7.159.
3
Outcome of surgical resection in Klatskin tumors.肝门部胆管癌的手术切除治疗效果。
World J Gastrointest Oncol. 2013 Jul 15;5(7):147-58. doi: 10.4251/wjgo.v5.i7.147.
4
Principles of surgical resection in hilar cholangiocarcinoma.肝门部胆管癌的手术切除原则。
World J Gastrointest Oncol. 2013 Jul 15;5(7):139-46. doi: 10.4251/wjgo.v5.i7.139.
5
Risk factors and classifications of hilar cholangiocarcinoma.肝门部胆管癌的风险因素和分类。
World J Gastrointest Oncol. 2013 Jul 15;5(7):132-8. doi: 10.4251/wjgo.v5.i7.132.
6
Laparoscopic staging in hilar cholangiocarcinoma: Is it still justified?腹腔镜肝门部胆管癌分期：是否仍有必要？
World J Gastrointest Oncol. 2013 Jul 15;5(7):127-31. doi: 10.4251/wjgo.v5.i7.127.
7
Radiological diagnosis and staging of hilar cholangiocarcinoma.肝门部胆管癌的放射学诊断和分期。
World J Gastrointest Oncol. 2013 Jul 15;5(7):115-26. doi: 10.4251/wjgo.v5.i7.115.
8
Evolution of surgical treatment for perihilar cholangiocarcinoma: a single-center 34-year review of 574 consecutive resections.肝门部胆管癌外科治疗的演变：单中心 34 年 574 例连续切除术回顾。
Ann Surg. 2013 Jul;258(1):129-40. doi: 10.1097/SLA.0b013e3182708b57.
9
A common language to describe perihilar cholangiocarcinoma.
Br J Surg. 2012 Jul;99(7):885-6. doi: 10.1002/bjs.8782. Epub 2012 May 3.
10
The impact of portal vein resection on outcomes for hilar cholangiocarcinoma: a multi-institutional analysis of 305 cases.门静脉切除对肝门部胆管癌预后的影响：305 例多机构分析。
Cancer. 2012 Oct 1;118(19):4737-47. doi: 10.1002/cncr.27492. Epub 2012 Mar 13.
Zotero 插件